guidelines in the management of ra n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Guidelines in the Management of RA PowerPoint Presentation
Download Presentation
Guidelines in the Management of RA

Loading in 2 Seconds...

play fullscreen
1 / 88

Guidelines in the Management of RA - PowerPoint PPT Presentation


  • 95 Views
  • Uploaded on

Guidelines in the Management of RA. Haya M. Al- Malaq Lecturer, Clinical Pharmacy Dept. Clinical Pharmacist Rheumatology Haya_malak@yahoo.com. Introduction .

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Guidelines in the Management of RA' - abia


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
guidelines in the management of ra

Guidelines in the Management of RA

Haya M. Al-Malaq

Lecturer, Clinical Pharmacy Dept.

Clinical Pharmacist Rheumatology

Haya_malak@yahoo.com

introduction
Introduction
  • Rheumatoid arthritis (RA) is an autoimmunedisorder of unknown etiology characterized by symmetric, erosive synovitis and, in some cases, extraarticularinvolvement. Most patients experience a chronic fluctuating course of disease that, despite therapy, may result in progressive joint destruction, deformity, disability, & even premature death.
epidemiology
Epidemiology
  • RA results in more than 9 million physician visits and more than 250,000 hospitalizations per year. Disability from RA causes major economic loss and can have a profound impact on families. RA affects 1% of the adult population this is due to low diagnosis (difficult to diagnose in early stages).
  • Females more than male.
pathophysiology1
Pathophysiology
  • The cause of RA is still unknown, it could be infection & as the case of other autoimmune diseases the immune system (AB to organism) begins to attack its self (molecules in the synovium that looks like the offending organism) Some infectious organisms mentioned in this context have been Mycoplasma, Erysipelothrix, parvovirus B19 and rubella, EBV, human herpes virus.
pathophysiology2
Pathophysiology
  • Genetic predisposition is important, risk factors include cigarette smoking, hormonal factors (more in women).
  • Once triggered, B lymphocytes produce immunoglobins, & RF of the IgG & IgM classes that are deposited in the tissue, this subsequently leads to the activation of the serum complement cascade & recruitment of the phagocytic arm of the immune response, which further exacerbates the inflammation of the synovium, leading to edema, vasodilation and infiltration by activated T-cells
pathophysiology3
Pathophysiology
  • Early and intermediate molecular mediators of inflammation include TNF-α, IL-1,6,8,15, transforming growth factor beta, fibroblast growth factor and platelet-derived growth factor.
  • Synovial macrophages and dendritic cells further function as antigen presenting cells by expressing MHC class II molecules, leading to an established local immune reaction in the tissue.
pathophysiology4
Pathophysiology
  • The disease progresses in concert with formation of granulation tissue at the edges of the synovial lining (pannus) with extensive angiogenesis and production of enzymes that cause tissue damage.
  • Once the inflammatory reaction is established, the synovium thickens, the cartilage and the underlying bone begins to disintegrate and evidence of joint destruction accrues.
synovitis
Synovitis
  • Most commonly affected joints are, small joints (including the hands, feet and cervical spine), but larger joints (shoulders, knees etc) can also be involved; the pattern of joint involvement can differ from patient to patient.
  • Inflammation in the joints manifests itself as a soft, "doughy" swelling, pain, tenderness to palpation and movement, local warmth, and functional impairment.
  • Morning stiffness is often a prominent feature and may last for more than an hour
deformity
Deformity
  • The fingers are typically deviated towards the little finger (ulnar deviation) and can assume unnatural shapes.
  • Classical deformities are the Boutonniere deformity
  • swan neck deformity
  • The thumb may develop a "Z-Thumb" deformity
extra articular
Extra-articular
  • general tiredness and lassitude,
  • low-grade fever,
  • elevated ESR, and anemia.
  • Extra-articularmanifestations occur in about 15% of patients
  • Hepatosplenomegaly which may occur with concurrent leukopenia and is then referred to as Felty's syndrome,.
  • lymphocytic infiltration affecting the salivary &lacrimal glands (Sjögren's syndrome).
  • pericarditis, pleurisy, alveolitis, scleritis, and subcutaneous nodules.
diagnostic criteria
Diagnostic Criteria

The ACR has defined the following criteria (>4) for the classification of RA:

  • Morning stiffness of >1 hour most mornings for at least 6 weeks.
  • Arthritis and soft-tissue swelling of >3 of 14 joints/joint groups, present for at least 6 weeks
  • Arthritis of hand joints, present for at least 6 weeks
  • Symmetric arthritis, present for at least 6 weeks
  • Subcutaneous nodules in specific places
  • Rheumatoid factor at a level above the 95th percentile
  • Radiological changes suggestive of joint erosion
blood test
Blood Test
  • RF (patients can be seronegative RA), not very specific test, 80% -ve in the 1st yr.
  • anti-citrullinated protein antibodies (ACPA), more specific, can detect pt in early stages or even before occurrence of the disease.
  • ESR, CRP, CBC, RF, liver enzyme, ANA, Ferritin can reveal hemochromatosis.
prognosis
Prognosis
  • Selection of the treatment regimen requires a assessment of prognosis. Poor prognosis is suggested by

earlier age at disease onset, high titer of RF, elevated ESR, and swelling of 20 joints .

  • Extraarticularmanifestations of RA may also indicate poor prognosis.
prognosis1
Prognosis
  • Studies have shown that patients with active, polyarticular, RF-positive RA have a 70% probability of developing joint damage or erosions within 2 years of the onset of disease
goals of management
Goals of Management
  • RA are to preventor control joint damage by inducing complete remission.
  • Prevent loss of function.
  • Decrease pain.
  • Maximize the QOL.
complete remission is absence of
Complete Remission Is Absence of:
  • 1) symptoms of active inflammatory joint pain
  • 2) morning stiffness
  • 3) fatigue,
  • 4) synovitis on joint examination
  • 5) progression of radiographic damage on sequential radiographs
  • 6)elevation of ESR or CRP levels
patient education
Patient education
  • It is a chronic disease.
  • Risks of joint damage and loss of function
  • Reviewing the risks and benefits of existing treatment modalities.
  • Periods of rest, job modification, time off from work, changes in occupation, or termination of work may be necessary
patient education1
Patient education
  • Surgery
  • Longitudinal treatment plan
  • Treatment options
  • Cost
  • Adverse effects
  • Expected time of response
non pharmacological tx
Non-Pharmacological Tx
  • Patient education.
  • Instruction in joint protection,
  • conservation of energy,
  • home program of joint range of motion
  • strengthening exercises
  • Regular participation in dynamic and even aerobic conditioning exercise programs
general guidelines
General Guidelines
  • NSAIDs, glucocorticoidjoint injection, and/or low-dose prednisone may be considered for control of symptoms.
  • The majority of patients with newly diagnosed RA should be started on DMARD therapy within 3 months of diagnosis.
general guidelines1
General Guidelines
  • DMARD control not cure so periodic assessment is required for efficacy & SE & therapy modification.
  • If disease activity is confined to one or a few joints, then local glucocorticoid injection may help. For patients with severe symptoms, systemic glucocorticoids may need to be initiated, or the dosage may need to be increased, for a short period of time.
  • Try to avoid narcotic addiction.
general guidelines2
General Guidelines
  • Pharmacologic therapy for RA often consists of combinations of NSAIDs, DMARDs, and/or glucocorticoids.
nsaids
NSAIDs
  • These agents have analgesic and antiinflammatory properties but do not alter the course of the disease or prevent joint destruction, so not used alone.
  • Choice of available agents is based on considerations of efficacy, safety, convenience, and cost.
  • Selective vr non-selective, no difference, cost.
risk factors for nsads se
Risk factors for NSADs SE
  • advanced age.
  • history of ulcer.
  • concomitant use of corticosteroids or anticoagulants
  • higher dosage of NSAID
  • use of multiple NSAIDs
  • serious underlying disease
approaches to reduce se
Approaches to reduce SE
  • use of low-dose prednisone instead of an NSAID,
  • use of a nonacetylatedsalicylate,
  • use of a highly selective COX-2 inhibitor,
  • or use of a combination of an NSAID and a gastroprotective agent as: H2 blocker, PPI, PG analogue
dmards
DMARDs
  • hydroxychloroquine (HCQ),
  • sulfasalazine (SSZ),
  • methotrexate (MTX),
  • leflunomide
  • etanercept
  • infliximab.
  • azathioprine (AZA)
  • D-penicillamine (D-Pen)
  • gold salts
  • minocycline
  • cyclosporine.
many factors influence the choice of dmard
Many factors influence the choice of DMARD
  • relative efficacy
  • Convenience of administration,
  • requirements of the monitoring program,
  • costs of the medication and monitoring
  • time until expected benefit
  • frequency
  • seriousness of adverse reactions.
  • Patient factors (compliance, diseases, prognosis, pregnancy/lactation).
dmards1
DMARDs
  • HCQ or SSZ first,
  • active disease or poor prognosis, MTX or combination therapy.
  • MTX alone or in combination should be included in patient with no MTX.
  • HCQ is indicated for milder disease, no monitoring (ophtha exam).
  • SSZ act more quickly, start gradually, watch for leucopoenia.
dmards2
DMARDs
  • Most select MTX as initial therapy esp. in severely active disease, CI: liver disease, renal impairment, lung disease, or alcohol abuse, monitor liver fx, contraception is recommended.
  • leflunomide as an alternative to MTX as monotherapy, especially for patients who cannot tolerate MTX, long t1/2, can be combined e MTX for max effect.
dmards3
DMARDs
  • AZA is rarely used
  • D-Pen is effective but its use is limited, in part, by an inconvenient dosing schedule.
dmards4
DMARDs
  • IM gold treatment is effective but injections are required every week for 22 weeks before less-frequent maintenance dosing is initiated, oral gold need 6 m to be effective.
  • Tetracyclines(minocycline), may be effective, needs more research.
  • Cyclosporine is beneficial as monotherapy and has short-term efficacy similar to that of D-Pen. The use of cyclosporine, however, has been limited by its toxicity, HTN & renal toxicity.
dmards5
DMARDs
  • Staphylococcal protein A immunoadsorption. Extracorporeal
  • immunoadsorption of plasma against astaphylococcal protein A column was reported to be efficacious in a portion of patients with severe refractory RA .
  • Given the difficulty and cost of administering weekly treatments for 12 weeks, the limited duration of the response, and the high frequency of side effects, this treatment should be considered only for patients with refractory RA in whom treatment with several DMARDs has failed.
slide52

Glucocorticoids. Low-dose oral glucocorticoids(10 mg of prednisone daily, or the equivalent) and local injections of glucocorticoids are highly effective for relieving symptoms in patients with active RA.

  • Discuss ADRs.
  • 1,500 mg of elemental calcium/day ,400–800 IU of vitamin D/day.
  • Hormone replacement therapy
  • bisphosphonates
biological agents
Biological Agents
  • Anti–tumor necrosis factor (anti-TNF-alpha)- biological agents etanercept and infliximab are beneficial in combination with MTX, avoid in TB, watch for infx, high cost.
  • Adalimumab: new agent
  • IL-1 receptor antagonist:Anakinra, modest effect.
combination therapy
Combination therapy
  • Cyclosporine plus MTX
  • MTX, HCQ, and SSZ
  • Plus lo dose CS
practice points
Practice points
  • glucocorticoids can offer immediate short-term relief and can serve as anadjunct to existing DMARD therapy.
  • the impact of glucocorticoids on structural damage and their optimal role in the management of RA require further investigation.
practice points1
Practice points
  • MTX remains the standard of therapy for both early and established RA ???
  • MTX is effective as both monotherapy and in combination therapy
  • a step-up approach has been successful in improving clinical response and slowing radiographic progression
practice points2
Practice points
  • TNF-a inhibitors produce prompt clinical response and can slow radiographic progression
  • infections, including opportunistic infections, should be watched for and, if found, treated aggressively in patients receiving TNF-a inhibitors
slide61

These guidelines are drawn from a synthesis of expert opinion, a survey of rheumatologists, published guidelines, and, whenever possible, data on toxicity.

slide62

Toxicity may range from mild to serious and from reversible to irreversible.

  • We define rare toxicities as those which occur in <1% of patients using the agent, uncommon in 1-10%, and common in >10%.
toxicities of drugs used in ra that require monitoring include
Toxicities of drugs used in RA that require monitoring include:
  • Gastrointestinal (GI) bleeding.
  • Hypertension.
  • Hyperglycemia.
  • Macular damage.
  • Renal damage.
  • Hepatotoxicity.
  • Myelosuppression.
reduction in the incidence severity unfavourable outcomes of these toxicities can be attempted by
Reduction in the incidence, severity, & unfavourable outcomes of these toxicities can be attempted by
  • 1) pretreatment assessment to identify patients with risk factors for toxicity.
  • 2) careful patient & physician education about safe dosage & S&S of toxicity
  • 3) appropriate monitoring with physician follow up & periodic lab studies.
nsaids toxicities
NSAIDs Toxicities
  • dyspepsia (common).
  • gastric or small bowel bleeding or ulceration (uncommon).
  • renal insufficiency, confusion, depression, rash, headache, and hepatic toxicity (rare).
nsaids toxicities1
NSAIDs Toxicities
  • reversibly inhibit platelet function and prolong bleeding time.
  • Patients with prior aspirin hypersensitivity are also at risk for developing bronchial spasms (rare).
  • There appear to be few differences in the frequency of serious toxicities among the different NSAIDs
nsaids toxicities2
NSAIDs Toxicities

Renal complications:

  • High-risk groups for renal toxicity include
  • the elderly, particularly those receiving diuretics.
  • patients with preexisting renal disease, CHF, cirrhosis, atherosclerotic heart disease, or any altered physiologic state in which renal blood flow is being maintained by compensatory vasodilatation.
nsaids toxicities3
NSAIDs Toxicities

To prevent renal toxicity in patients who are at risk:

  • NSAIDs should be started in modest doses & then carefully increased.
  • Patients should be instructed to report if signs of fluid retention evidenced by weight gain or edema develop, if they become ill & dehydrated, or if they are to begin treatment with diuretics or ACE).
nsaids toxicities4
NSAIDs Toxicities

Renal complications:

  • monitor SrCr in high-risk patients every wk for several wks after Tx is started.
  • The average time of drug exposure has been 6.6 m for NSAID-induced nephrotic syndrome and 15 days for allergic interstitial nephritis.
nsaids toxicities5
NSAIDs Toxicities

Liver toxicity:

  • may cause elevation of liver enzyme levels, but severe hepatotoxicity is rare.
  • There is no evidence that abnormal findings on LFT in the absence of clinical symptoms change the outcome or are associated with serious hepatotoxicity
  • Liver function should be monitored in patients who are treated with diclofenac or in those who have intrinsic liver disease or in whom it is suspected.
hydroxychloroquine hcq
Hydroxychloroquine (HCQ)
  • The major toxicity of antimalarial agents is retinal damage (rare), which can lead to visual impairment.
  • It has less toxicity to be monitored.
  • Goal for monitoring is to detect early reversible retinal toxicity.
hydroxychloroquine hcq1
Hydroxychloroquine (HCQ)

The major risk factor for retinal toxicity appears to be the combination of:

  • cumulative dose >800 gm.
  • age >70 years (increased prevalence of macular disease).
  • HCQ dosage of >6.0-6.5 mg/kg/d, in patients with abnormal hepatic or renal function.
hydroxychloroquine hcq2
Hydroxychloroquine (HCQ)
  • Patient should report any visual symptoms.
  • Baseline evaluation < 40 is not required.
  • After 6 month of therapy should do evaluation then every 6-12 months.
  • Patients with abnormal RF or those who have received HCQ > 10 years require more frequent ophthalmologic evaluation.
sulfasalazine ssz
Sulfasalazine (SSZ)

Hematologic toxicities of SSZ:

  • leukopenia (1-3%)
  • thrombocytopenia (rare).
  • hemolysis in patients with (G6PD) deficiency.
  • agranulocytosis (rare).
  • aplastic anemia (rare)
sulfasalazine ssz1
Sulfasalazine (SSZ)
  • Leukopenia is most likely to occur in the first 6 m of TX, may occur later.
  • Early dosage reduction &/or cessation may reverse leukopenia.
  • Patients should be questioned about allergies to sulfa drugs & cautioned about oligospermia.
sulfasalazine ssz2
Sulfasalazine (SSZ)
  • The main goal of monitoring is to detect hematological toxicities.
  • a baseline assessment of AST or ALT in patients with known or suspected liver disease.
methotrexate mtx
Methotrexate (MTX)
  • The most serious toxicities of MTX include hepatic fibrosis (rare) & cirrhosis (rare), pneumonitis (uncommon), & myelosuppression.
methotrexate mtx1
Methotrexate (MTX)
  • Independent risk factors for the development of serious liver disease in patients with RA include:
  • age
  • duration of therapy,
  • obesity,
  • diabetes,
  • alcohol intake,
  • prior history of hepatitis B or C
methotrexate mtx2
Methotrexate (MTX)
  • Prevention of hepatic fibrosis and cirrhosis includes:
  • avoidance of MTX in patients with liver disease risk factor.
  • In patients with suspected liver disease, a pretreatment liver biopsy should be obtained.
  • Avoid alcohol consumption while taking MTX.
  • Patients should report symptoms of jaundice or dark urine.
  • Liver biopsy is recommended for patients with liver function abnormalities that persist during treatment with, or following D/C of MTX.
methotrexate mtx3
Methotrexate (MTX)
  • Risk factors for myelosuppression include the use of antifolate agents such as trimethoprim, the presence of folate deficiency, and renal insufficiency.
  • CBC & RF q4-8wks.
  • Review of a radiograph obtained within 1 year prior to the initiation of MTX therapy is recommended to determine if preexisting lung disease is present and to provide a baseline for future comparison
  • Use FA supplementation.
  • pregnancy should be avoided.
gold compounds
Gold compounds
  • The major serious toxicities-hematologic, renal, and pulmonary- rare.
  • monitoring should be considered if protein excretion is >500 mg/24 hours.
  • Oral less toxic than parentral.
  • Patients need to be educated about the need for frequent monitoring & for reporting of rash, mucositis, hematuria or bleeding, or any new illness while receiving gold.
d penicillamine dp
D-penicillamine (DP)
  • rash (common), stomatitis (common), dysgeusia or metallic taste (common), myelosuppression (especially thrombocytopenia) (rare), & proteinuria (rare).
  • renal failure (rare) and induction of autoimmune syndromes such as SLE.
  • Slowly increasing the dosage of DP by 125-250-mg increments every 3 months up to 750 mg/d to decrease thrombocytopenia.
  • Patients taking DP should report any new symptoms.
azathioprine aza
Azathioprine (AZA)
  • capable of inducing myelosuppression at dosages used to treat RA (1-2 mg/kg/day).
  • The rationale for monitoring is to decrease the incidence and severity of myelosuppression.
  • Risk factors include: concomitant allopurinol or ACE inhibitors & RF.
  • Prevention: reducing the dose to 1/4 with concomitant allopurinol, avoiding ACEI, & decreasing the dose in patients with renal insufficiency.
glucocorticoids
Glucocorticoids
  • increased appetite, weight gain, fluid retention, acne, cushingoidfacies, HTN, diabetes, atherosclerosis, glaucoma & cataract, osteoporosis, a vascular necrosis, increased susceptibility to infection, & impaired wound healing.
glucocorticoids1
Glucocorticoids

Patient's risk factors for steroid AE:

  • family Hx of diabetes,
  • established HTN or diabetes,
  • preexisting cataract(s) or glaucoma,
  • low BMD,
  • Hx of osteoporotic fracture, or significant osteoporosis risk factors such as premature menopause.
glucocorticoids2
Glucocorticoids
  • Initial assessment may include measuring Wt & BP,
  • serum glucose and cholesterol levels,
  • in patients at high risk for osteoporosis, consideration of BMD measurement & supplementation with calcium & vit D.
  • Baseline eye examination in patients over the age of 65 or with a family history of glaucoma.
antirheumatic agents and teratogenicity lactation and fertility
Antirheumatic agents and teratogenicity, lactation, and fertility
  • The majority of RA patients are females and some are at a reproductive age.
  • Decisions regarding the use of medications in pregnancy require consideration of the risks & benefits to mother & fetus.